Abstract
A Phase II Study of Two Dose Levels of a Third-Generation Selective Estrogen Receptor Modulator (SERM) LY353381 in Women with Breast Cancer 1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have